Artera Expands Its Validated Multimodal AI Platform to Metastatic Hormone‑Sensitive Prostate Cancer (mHSPC)

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today ...

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...
Stocktwits on MSN

Tempus AI expands cancer platform with launch of ArteraAI prostate test for metastatic patients

Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

Prostate Health: Early Signs, Screening, And Treatment Awareness

Prostate health is vital for men over fifty as conditions like BPH, prostatitis, and cancer can affect urinary function and ...
Healio

Urine test may detect aggressive prostate cancer, eliminate need for some biopsies

Please provide your email address to receive an email when new articles are posted on . MyProstateScore 2.0 showed high sensitivity for detecting aggressive prostate cancer without the need for a ...
Morningstar

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...
Times Argus

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...